Given that significant activity was demonstrated even in tumors with an agnostic mechanism of resistance to EGFR TKIs, this novel agent could potentially be integrated into the future algorithm of EGFR mutant NSCLC as a third-line treatment after progression of the disease on TKIs and platinum-based chemotherapy with or without bevacizumab and atezolizumab (IMpower 150) [79,80,81,82]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.